Osteoporosis treatment: why ibandronic acid?
- 7 May 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 14 (10) , 1371-1381
Abstract
In this article, we have summarized the specific evidence on ibandronic acid (or ibandronate) efficacy, tolerability, and feasibility acquired from trials and clinical use.Keywords
This publication has 88 references indexed in Scilit:
- Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease — The DIVINE studyBone, 2011
- Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administrationJournal of Bone and Mineral Research, 2011
- Evidence of Sustained Vertebral and Nonvertebral Antifracture Efficacy with Ibandronate Therapy: A Systematic ReviewTherapeutic Advances in Musculoskeletal Disease, 2011
- Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoidArthritis Research & Therapy, 2010
- Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population StudiesCalcified Tissue International, 2010
- Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatmentClinical Interventions in Aging, 2009
- Adherence to monthly and weekly oral bisphosphonates in women with osteoporosisOsteoporosis International, 2009
- Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for OsteoporosisMayo Clinic Proceedings, 2007
- Ibandronate: A Clinical Pharmacological and Pharmacokinetic UpdateThe Journal of Clinical Pharmacology, 2004
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004